Pilihan
AWG Kibarkan Bendera Indonesia-Palestina di Gunung Raung
Geneva College of Longevity Science Launches the World's First PhD in Longevity Sciences
GENEVA and CONSTANȚA, Romania, April 24, 2026 (GLOBE NEWSWIRE) -- The Geneva College of Longevity Science (GCLS) today announced the launch of the world’s first PhD in Medicine with a specialization in Longevity Sciences, developed in academic partnership with Ovidius University of Constanța.
The four-year doctoral program represents a major milestone in the evolution of longevity science, designed to train a new generation of physician-scientists and researchers focused on preventive, healthspan-oriented healthcare and the clinical translation of aging biology.
“Longevity medicine has reached a point where the science is advancing faster than the institutions required to translate it responsibly into healthcare,” said Dominik Thor, President of GCLS. “With this PhD, we are building the academic and research infrastructure needed to support the field’s long-term development.”
From Emerging Science to Medical Discipline
Advances in aging biology, genomics, and digital health have created new opportunities to move beyond reactive care toward proactive risk management and healthspan preservation. Despite this progress, formal academic pathways in longevity science have remained limited.
The PhD in Longevity Sciences addresses this gap by providing structured doctoral training in:
Biology of aging and longevity pathways
Biomarkers and measurement of biological age
Preventive, risk-stratified, and healthspan-oriented medicine
Epidemiology of aging populations
Ethical, regulatory, and health system considerations
The program reflects a broader shift in medicine - from treating disease after onset to addressing the underlying drivers of disease across the lifespan - and is grounded in evidence-based medicine.
By embedding longevity science within a formal doctoral framework, GCLS and Ovidius University aim to:
Support the development of evidence-based longevity medicine
Train researchers capable of translating science into clinical practice
Contribute to sustainable, prevention-focused healthcare systems
Establish academic standards in an emerging global field
Applications Now Open
The program is designed for graduates with a strong academic background and a research interest in aging biology, preventive medicine, or related fields.
More information and application details:
https://www.gcls.study/phd-programme
About Geneva College of Longevity Science (GCLS)
The Geneva College of Longevity Science (GCLS) is a Swiss-based higher education institute dedicated to longevity science, preventive medicine, and the clinical translation of aging biology into evidence-based healthcare practice.
Learn more: https://www.gcls.study
Press Contact
Geneva College of Longevity Science (GCLS)
Email: press@gcls.study
Website: https://gcls.ai
Copyright 2026 GlobeNewswire, Inc.
.png)

Berita Lainnya
*THE PARC DES PRINCES AS YOU’VE NEVER SEEN IT BEFORE - Paris Saint-Germain Legends, ................
Omni Bridgeway Mengangkat Peter Galgay sebagai Head of Commercial Strategy and Capital Solutions
Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare
"Hong Kong Mega 8" Showcases the City's Allure as the "Events Capital of Asia"
Meltwater Wins 2026 PRWeek Global Award for “Best PR Software or AI Platform”
Scrap the Ban, Keep the Controls: CAPHRA's Message to Bangladesh
TestMu AI Introduces SmartUI Build Data Export for Visual Testing Workflows
Boehringer Ingelheim introduces LENZELTA: A new vaccine advancing mastitis prevention in dairy cows
Bitget Brings Institutional-Grade Stablecoin Yield to All Users with USDGO, Offering Up to 4.3% APR
Qiang Cai and Ricardo Andre Galendi Junior win the 12th IBFD Frans Vanistendael Award for International Tax Law
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in Adults